BioSpace News Archive

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the completion of the clinical stage of its Phase 1, single ascending dose escalation trial of TNX-1500 (Fc-modified humanized anti-CD40L monoclonal antibody, or mAb)* in healthy volunteers.

Idorsia Ltd announced that it has entered into agreements for a significant global research and development collaboration with Viatris Inc.

Viatris Inc. and Idorsia Ltd announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will present at the scientific conference Bayes@Lund 2024 on March 7, 2024.

Allarity Therapeutics, Inc., a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, is pleased to announce that it has been invited to present at Biomarkers 2024.

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced the launch of the Riskguard™ hereditary cancer test in the United States.

G1 Therapeutics, Inc., a commercial-stage oncology company, provided a corporate and financial update for the fourth quarter and full year ended December 31, 2023.

Sage Therapeutics, Inc. announced today that the Company will present at the following upcoming investor conferences in March.

Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference.

Zentalis® Pharmaceuticals, Inc. announced that Zentalis management will participate in several upcoming investor conferences.